LUNG Pulmonx

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at .

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit .

Contact

Brian Johnston

Gilmartin Group



EN
13/02/2025

Underlying

LUNGPulmonx

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pulmonx

 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Report First Quarter 2025 Financial Results on April 30, 20...

Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025 REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of ...

April 16, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 44.09
0BOE BOEING COMPANY ...
PMT PennyMac Mortga... ... (+33)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

0BOE BOEING COMPANY (THE)
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
BKD BROOKDALE SENIOR LIVING INC.
WBA WALGREENS BOOTS ALLIANCE INC
PLOW DOUGLAS DYNAMICS INC.
NSP INSPERITY INC.
NEU NEWMARKET CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
INTC INTEL CORPORATION
HSY HERSHEY COMPANY
DLTR DOLLAR TREE INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BAX BAXTER INTERNATIONAL INC.
SBL SAFE BULKERS INC.
CYH COMMUNITY HEALTH SYSTEMS INC.
LKO LAKES OIL N.L.
AWK AMERICAN WATER WORKS COMPANY INC.
CWT CALIFORNIA WATER SERVICE GROUP
TNC TENNANT COMPANY
NGVT INGEVITY CORPORATION
KALV KALVISTA PHARMACEUTICALS
SSTI SHOTSPOTTER
VIAC VIACOMCBS INC. CLASS B
STTK SHATTUCK LABS
CSTM CONSTELLIUM SE CLASS A
LUNG PULMONX
BBWI BATH & BODY WORKS INC
UWMC UWM HLDGS CORP
UDMY UDEMY INC
AMGN AMGEN INC
NYMT NEW YORK MORTGAGE TRUST INC.
HSHP HIMALAYA SHIPPING LTD.
PCH PICOMAT PLASTIC JSC
02/26/25 February 26, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Res...

Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the ...

February 19, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Science...

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at . About Pulm...

February 13, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results ...

Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be avail...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch